Showing results (611-620 of 2,280) with videos related to

Sort By:
Pageof 228
HIV Medicine|January 26, 2018
Patient perspectives on de-simplifying their single-tablet co-formulated antiretroviral therapy for societal cost savingsH B Krentz, S Campbell, V C Gill, et al.
HIV Medicine|December 15, 2018
High-risk behaviours, and their associations with mental health, adherence to antiretroviral therapy and HIV parameters, in HIV-positive men who have sex with menErm Pool, A Winston, E Bagkeris, et al.
HIV Medicine|February 20, 2007
Cervical lipomatosis in HIV-infected patients: a case-control studyR Palacios, M J Galindo, J A Arranz, et al.
HIV Medicine|February 20, 2007
Mitochondrial DNA assessment in adipocytes and peripheral blood mononuclear cells of HIV-infected patients with lipodystrophy according to a validated case definitionM Casula, M van der Valk, F W Wit, et al.
HIV Medicine|February 20, 2007
Haemoglobin and albumin as markers of HIV disease progression in the highly active antiretroviral therapy era: relationships with genderS Shah, C J Smith, F Lampe, et al.
HIV Medicine|February 20, 2007
Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatmentP Srasuebkul, C Ungsedhapand, K Ruxrungtham, et al.
HIV Medicine|September 2, 2006
Pulmonary Kaposi sarcoma in the era of highly active antiretroviral therapyC Palmieri, T Dhillon, C Thirlwell, et al.
HIV Medicine|September 2, 2006
HIV-1 reverse transcriptase (RT) genotypic patterns and treatment characteristics associated with the K65R RT mutationS Boucher, P Recordon-Pinson, J M Ragnaud, et al.
HIV Medicine|July 31, 2007
Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006K Smyth, J S Affandi, J C McArthur, et al.
HIV Medicine|April 28, 2007
Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletionJ J Laurichesse, A Persoz, I Theodorou, et al.
Pageof 228